TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04579315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group; NNRD group
Description: The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
Study: NCT00592202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of an adjustable gastric band
Description: Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
Study: NCT02590107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily food diaries
Description: Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
Study: NCT04629742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seawater Pizza
Description: A seawater pizza administered to 12 healthy subjects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pizza
Description: A standard pizza administered to 12 healthy subjects
Study: NCT01602016

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic Acid and placebo
Description: Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
Study: NCT03870477

Intervention type: DEVICE
Group type: OTHER
Intervention: THP Hip Fracture Plating System with telescoping lag screws
Description: The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
Study: NCT01010022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Description: Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% hydroxyethyl starch 70/0.5 (Salinhes®)
Description: Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
Study: NCT02954159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
Study: NCT03978845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
Study: NCT03747055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group problem management plus
Description: Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
Study: NCT01233258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) on demand
Description: Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) on demand
Description: Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis low-dose
Description: Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis low-dose
Description: Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Study: NCT03747055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
Study: NCT01233258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis high-dose
Description: Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis high-dose
Description: Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Study: NCT02572401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAND HIV Risk Reduction Intervention
Description: STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAND HIV Risk Reduction Intervention
Description: STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
Study: NCT00853775

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT04660305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT278
Description: Concentrated rapid acting insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT278
Description: Concentrated rapid acting insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid
Description: Rapid acting insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid acting insulin aspart
Study: NCT01406743

Intervention type: DEVICE
Intervention: EOS™ Acquisition
Description: Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
Study: NCT04623112

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aid feature: Frequency Compression
Description: FC Deactivated/Activated \& set to default/Activated \& set to hearing loss

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid feature: Frequency Compression
Description: FC Deactivated/Activated \& set to default/Activated \& set to hearing loss

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid feature: Frequency Compression
Description: FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
Study: NCT03812107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Treatment Approach
Description: The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
Study: NCT01271179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential perfusion with ipv Ross solution and UW solution
Description: Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
Study: NCT00807144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kidney transplant maintenance immunosuppression
Description: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
Study: NCT03812107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Treatment Approach
Description: After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
Study: NCT03975036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib Hydrochloride Capsules
Study: NCT00648349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Delayed-Release Tablets 20 mg
Description: 20mg, single dose fasting
Study: NCT01271179

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sole perfusion with UW solution
Description: Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
Study: NCT04269733

Intervention type: DEVICE
Intervention: Right ventricular pacing
Description: Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
Study: NCT00536484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: 4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Study: NCT01633502

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional circulatory support
Description: Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impella CP
Description: Control group treated with Impella CP for a minimum of 48 hrs.
Study: NCT02434224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: 2 to 3 sessions per week of individualized creative music therapy
Study: NCT01370213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
Study: NCT03975036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 antibody
Description: Pembrolizumabinjection
Study: NCT01370213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Graft/Anti-thymocyte globulin
Description: Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor TCR α/β-depleted Graft/ATG
Description: Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
Study: NCT03892213

Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Description: Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.

Intervention type: DRUG
Group type: OTHER
Intervention: E1224
Description: E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly.
Study: NCT04016337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverages
Description: The beverages were all made with lemon and maqui extracts, and different sweeteners

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverages
Description: The beverages were all made with lemon and maqui extracts, and different sweeteners

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverages
Description: The beverages were all made with lemon and maqui extracts, and different sweeteners
Study: NCT00925301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat hydrochloride
Description: Oral capsule QOD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule QOD
Study: NCT02373670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of positive deviance behaviors
Description: Using locally derived positive deviance findings to inform a behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of healthy behaviors
Description: Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
Study: NCT04816630

Intervention type: DEVICE
Intervention: CBC-Diff Monocyte Volume Width Distribution
Description: MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
Study: NCT02191475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopeptide plus carbapenem
Description: The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haizheng Li Xing ® plus tazocin ®
Description: Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
Study: NCT03347552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME
Description: Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care.
Study: NCT01685541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum After Visit Summary Content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate After Visit Summary Content
Study: NCT01095211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-vitamin complex
Description: 5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
Study: NCT00648349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex® Delayed-Release Tablets 20 mg
Description: 20mg, single dose fasting
Study: NCT01095211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B-vitamin complex
Description: 5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
Study: NCT05948644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
Study: NCT02378597

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Resiliency Intervention
Description: 4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
Study: NCT01368094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain removal at D4
Description: If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drain removal
Description: If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
Study: NCT02256995

Intervention type: DEVICE
Intervention: uChek
Description: The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
Study: NCT00637351

Intervention type: PROCEDURE
Intervention: Blood sample
Description: One blood sample will be collected at the time of screening for subjects

Intervention type: PROCEDURE
Intervention: Blood sample
Description: One blood sample will be collected at the time of screening for subjects

Intervention type: PROCEDURE
Intervention: Urine sample
Description: One urine sample will be collected at the time of screening for subjects

Intervention type: PROCEDURE
Intervention: Urine sample
Description: One urine sample will be collected at the time of screening for subjects
Study: NCT01685541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum After Visit Summary Content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual AVS